Dorian LPG
LPG
YETI Holdings
YETI
Workday
WDAY
Collegium Pharmaceutical
COLL
LIFE HEALTHCARE GROUP HOLDINGS UNSPON ADR EA REPR 4 ORD ZAR0.00
LTGHY
US Stock MarketDetailed Quotes
CMMB Chemomab Therapeutics
- 1.440
- -0.060-4.00%
Close Mar 18 16:00 ET
- 1.420
- -0.020-1.39%
Post 16:10 ET
27.15MMarket Cap-1.67P/E (TTM)
1.489High1.415Low55.58KVolume1.450Open1.500Pre Close80.10KTurnover0.47%Turnover RatioLossP/E (Static)18.86MShares2.55052wk High2.01P/B17.02MFloat Cap0.57952wk Low--Dividend TTM11.82MShs Float184.000Historical High--Div YieldTTM4.96%Amplitude0.420Historical Low1.441Avg Price1Lot Size
Chemomab Therapeutics News
Oppenheimer Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $11
Chemomab Therapeutics (CMMB) Gets a Buy From Oppenheimer
Chemomab Therapeutics Analyst Ratings
Maxim Group Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Raises Target Price to $7
Maxim Group Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Raises Target Price to $7
Analysts Are Bullish on Top Healthcare Stocks: Chemomab Therapeutics (CMMB), Blueprint Medicines (BPMC)
Oppenheimer Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $11
Maxim Group Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $4
Oppenheimer Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Cuts Target Price to $11
Chemomab Therapeutics Analyst Ratings
Roth MKM Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $9
Roth MKM Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $9
Maxim Group Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $4
Chemomab Therapeutics (CMMB) Gets a Buy From Oppenheimer
Maxim Group Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $4
Roth MKM Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Raises Target Price to $9
Oppenheimer Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Raises Target Price to $13
Chemomab Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Chemomab Therapeutics (CMMB), Fate Therapeutics (FATE) and Disc Medicine (IRON)
Analysts Offer Insights on Healthcare Companies: Andlauer Healthcare Group (OtherANDHF), ACADIA Pharmaceuticals (ACAD) and Chemomab Therapeutics (CMMB)